For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a lower risk for venous thromboembolism (VTE).

A new study provides more evidence that GLP-1 RAs don’t raise the risk for pancreatic cancer and may in fact offer some protection.

Q3 2024 Earnings Call Transcript November 14, 2024 Operator: Good afternoon, and welcome to Fractyl Health’s Third Quarter Financial Results and Business Updates Call. As a reminder, this conference ...

The study predicts devastating trends at the population level.

While glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve outcomes in CKM syndrome, inequitable access (e.g., coverage, supply constraints) may worsen health disparities in CKM syndrome. Aims ...

GLP-1 drug shortages, driven by cosmetic and weight loss purposes, result in access disparities among individuals with ...

A new study supports the notion that the same mechanisms that help folks lose weight with Ozempic and its kin also work to ...

There have been a slew of studies recently supporting the notion that the same mechanisms that help folks lose weight ...

A recent study conducted in Sweden found that GLP-1 agonists such as Ozempic and Wegovy may help reduce alcohol consumption and related harms in individuals diagnosed with alcohol use disorder. Here ...

GLP-1RA prescription trends, real-world effectiveness, and predictors for access and rationing were highlighted at ...

The following is a summary of “Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized ...

GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.